1. Wallace, D. J. et al. A phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumab of patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).
2. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
3. Merrill, J. T. et al. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. Presented at the American College of Rheumatology 2008 Annual Scientific Meeting.
4. Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study (EXPLORER). Presented at the American College of Rheumatology 2008 Annual Scientific Meeting.
5. Furie, R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 60 (Suppl.), S429 (2009).